Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Program Official
Principal Investigator
Kathleen Yost Butler
Awardee Organization

Corewell Health
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Cancer Research Consortium of West Michigan (CRCWM)

The Cancer Research Consortium of West Michigan (CRCWM) is an NCI Community Oncology Research Program (NCORP) comprised of eleven hospitals and health systems and a medical school member. CRCWM covers the west half of Michigan and cares for almost 16,000 newly diagnosed cancer patients and their families per year. Formed from two experienced Community Clinical Oncology Programs (CCOPs) in 2014, CRCWM has a 50-year history of bringing cancer clinical trials and education to the community, continues to be a major accruer to National Cancer Institute (NCI) studies, and is acknowledged by the NCORP division as a highperformance program. With over 140 oncology physician investigators, 75 oncology nurse practitioners/ physician assistants, and a well-established research operations team of 40 research nurses and coordinators, CRCWM has the ability to enroll patients with cancer related diagnoses across the continuum and to address NCI goals of expanding participation of underrepresented individuals in clinical trials. This application reiterates our commitment to highquality research and ongoing alignment with the NCI Cancer Plan and initiatives. Strategic goals to meet this mission and vision include: 1. To maximize accrual of patients to cancer clinical trials sponsored by the NCI including priority studies for treatment, cancer control/prevention/screening, molecular/precision medicine, and imaging. 2. To be strong contributors to Cancer Care Delivery Research (CCDR). 3. To maximize the sharing of NCI scientific findings into clinical care through education and engagement of clinical partners and health systems. 4. To contribute to better understanding of health care gaps experienced by individuals who may be underrepresented (e.g., rural, adolescent/young adult, and elderly) within our communities. 5. To optimize our contribution to the national scientific research agenda by expanding our leadership and committee participation in the National Clinical Trials Network (NCTN)/NCORP research bases and the mentoring of young investigators. CRCWM is well-positioned to continue forward this next year with the scope of work demonstrated consistently throughout this grant cycle and by our long history of experience and success.

Publications

  • McLouth LE, Zheng Y, Smith S, Hodi FS, Rao UN, Cohen GI, Amatruda TT, Dakhil SR, Curti BD, Nakhoul I, Chandana SR, Bane CL, Marinier DE, Lee SJ, Sondak VK, Kirkwood JM, Tarhini AA, Wagner LI. Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2023 Jan;32(1):183-196. Epub 2022 Aug 27. PMID: 36029412
  • Comstock CE, Gatsonis C, Newstead GM, Snyder BS, Gareen IF, Bergin JT, Rahbar H, Sung JS, Jacobs C, Harvey JA, Nicholson MH, Ward RC, Holt J, Prather A, Miller KD, Schnall MD, Kuhl CK. Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. JAMA. 2020 Feb 25;323(8):746-756. PMID: 32096852
  • Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevich DA, Sledge GW, Cella D. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast cancer research and treatment. 2018 Jun;169(3):537-548. Epub 2018 Feb 17. PMID: 29455298